-
Je něco špatně v tomto záznamu ?
Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells
MA. Rodríguez-Hernández, P. de la Cruz-Ojeda, P. Gallego, E. Navarro-Villarán, P. Staňková, JA. Del Campo, O. Kučera, M. Elkalaf, TE. Maseko, Z. Červinková, J. Muntané,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- autofagie účinky léků MeSH
- buněčná smrt účinky léků MeSH
- buňky Hep G2 MeSH
- chemorezistence účinky léků MeSH
- hepatocelulární karcinom metabolismus patologie MeSH
- jaterní mitochondrie účinky léků metabolismus MeSH
- kaspasa 9 metabolismus MeSH
- lidé MeSH
- nádory jater metabolismus patologie MeSH
- oxid dusnatý metabolismus MeSH
- potkani Wistar MeSH
- PPARGC1A metabolismus MeSH
- proteinkinasy aktivované AMP metabolismus MeSH
- protinádorové látky farmakologie MeSH
- signální transdukce účinky léků MeSH
- sorafenib farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the fourth most frequent cause of cancer-related death worldwide. Sorafenib is the first line recommended therapy for patients with locally advanced/metastatic HCC. The low response rate is attributed to intrinsic resistance of HCC cells to Sorafenib. The potential resistance to Sorafenib-induced cell death is multifactorial and involves all hallmarks of cancer. However, the presence of sub-therapeutic dose can negatively influence the antitumoral properties of the drug. In this sense, the present study showed that the sub-optimal Sorafenib concentration (10 nM) was associated with activation of caspase-9, AMP-activated protein kinase (AMPK), sustained autophagy, peroxisome proliferator-activated receptor-coactivator 1α (PGC-1α) and mitochondrial function in HepG2 cells. The increased mitochondrial respiration by Sorafenib (10 nM) was also observed in permeabilized HepG2 cells, but not in isolated rat mitochondria, which suggests the involvement of an upstream component in this regulatory mechanism. The basal glycolysis was dose dependently increased at early time point studied (6 h). Interestingly, Sorafenib increased nitric oxide (NO) generation that played an inhibitory role in mitochondrial respiration in sub-therapeutic dose of Sorafenib. The administration of sustained therapeutic dose of Sorafenib (10 µM, 24 h) induced mitochondrial dysfunction and dropped basal glycolysis derived acidification, as well as increased oxidative stress and apoptosis in HepG2. In conclusion, the accurate control of the administered dose of Sorafenib is relevant for the potential prosurvival or proapoptotic properties induced by the drug in liver cancer cells.
CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas Spain
COST European Cooperation in Science and Technology Mitoeagle Action number CA15203 Brussels Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028110
- 003
- CZ-PrNML
- 005
- 20210114153014.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2020.113902 $2 doi
- 035 __
- $a (PubMed)32156660
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Rodríguez-Hernández, María A $u Institute of Biomedicine of Seville (IBIS), IBiS/Hospital University "Virgen del Rocío"/CSIC/University of Seville, Seville, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
- 245 10
- $a Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells / $c MA. Rodríguez-Hernández, P. de la Cruz-Ojeda, P. Gallego, E. Navarro-Villarán, P. Staňková, JA. Del Campo, O. Kučera, M. Elkalaf, TE. Maseko, Z. Červinková, J. Muntané,
- 520 9_
- $a Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the fourth most frequent cause of cancer-related death worldwide. Sorafenib is the first line recommended therapy for patients with locally advanced/metastatic HCC. The low response rate is attributed to intrinsic resistance of HCC cells to Sorafenib. The potential resistance to Sorafenib-induced cell death is multifactorial and involves all hallmarks of cancer. However, the presence of sub-therapeutic dose can negatively influence the antitumoral properties of the drug. In this sense, the present study showed that the sub-optimal Sorafenib concentration (10 nM) was associated with activation of caspase-9, AMP-activated protein kinase (AMPK), sustained autophagy, peroxisome proliferator-activated receptor-coactivator 1α (PGC-1α) and mitochondrial function in HepG2 cells. The increased mitochondrial respiration by Sorafenib (10 nM) was also observed in permeabilized HepG2 cells, but not in isolated rat mitochondria, which suggests the involvement of an upstream component in this regulatory mechanism. The basal glycolysis was dose dependently increased at early time point studied (6 h). Interestingly, Sorafenib increased nitric oxide (NO) generation that played an inhibitory role in mitochondrial respiration in sub-therapeutic dose of Sorafenib. The administration of sustained therapeutic dose of Sorafenib (10 µM, 24 h) induced mitochondrial dysfunction and dropped basal glycolysis derived acidification, as well as increased oxidative stress and apoptosis in HepG2. In conclusion, the accurate control of the administered dose of Sorafenib is relevant for the potential prosurvival or proapoptotic properties induced by the drug in liver cancer cells.
- 650 _2
- $a proteinkinasy aktivované AMP $x metabolismus $7 D055372
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a autofagie $x účinky léků $7 D001343
- 650 _2
- $a hepatocelulární karcinom $x metabolismus $x patologie $7 D006528
- 650 _2
- $a kaspasa 9 $x metabolismus $7 D053453
- 650 _2
- $a buněčná smrt $x účinky léků $7 D016923
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a chemorezistence $x účinky léků $7 D019008
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory jater $x metabolismus $x patologie $7 D008113
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a jaterní mitochondrie $x účinky léků $x metabolismus $7 D008930
- 650 _2
- $a oxid dusnatý $x metabolismus $7 D009569
- 650 _2
- $a PPARGC1A $x metabolismus $7 D000071248
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 650 _2
- $a sorafenib $x farmakologie $7 D000077157
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a de la Cruz-Ojeda, Patricia $u Institute of Biomedicine of Seville (IBIS), IBiS/Hospital University "Virgen del Rocío"/CSIC/University of Seville, Seville, Spain.
- 700 1_
- $a Gallego, Paloma $u Institute of Biomedicine of Seville (IBIS), IBiS/Hospital University "Virgen del Rocío"/CSIC/University of Seville, Seville, Spain.
- 700 1_
- $a Navarro-Villarán, Elena $u Institute of Biomedicine of Seville (IBIS), IBiS/Hospital University "Virgen del Rocío"/CSIC/University of Seville, Seville, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
- 700 1_
- $a Staňková, Pavla $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic; COST-European Cooperation in Science & Technology, Mitoeagle Action number: CA15203, Brussels, Belgium.
- 700 1_
- $a Del Campo, José A $u Institute of Biomedicine of Seville (IBIS), IBiS/Hospital University "Virgen del Rocío"/CSIC/University of Seville, Seville, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
- 700 1_
- $a Kučera, Otto $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic; COST-European Cooperation in Science & Technology, Mitoeagle Action number: CA15203, Brussels, Belgium.
- 700 1_
- $a Elkalaf, Moustafa $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Maseko, Tumisang E $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Červinková, Zuzana $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic; COST-European Cooperation in Science & Technology, Mitoeagle Action number: CA15203, Brussels, Belgium.
- 700 1_
- $a Muntané, Jordi $u Institute of Biomedicine of Seville (IBIS), IBiS/Hospital University "Virgen del Rocío"/CSIC/University of Seville, Seville, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain; COST-European Cooperation in Science & Technology, Mitoeagle Action number: CA15203, Brussels, Belgium; Department of General Surgery, "Virgen del Rocío" University Hospital/IBiS/CSIC/University of Seville, Seville, Spain. Electronic address: jmuntane-ibis@us.es.
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 176, č. - (2020), s. 113902
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32156660 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153011 $b ABA008
- 999 __
- $a ok $b bmc $g 1608445 $s 1119290
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 176 $c - $d 113902 $e 20200307 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20210105
